Company Profile
Laboratorio Farmaceutico Erfo S.p.A. specializes in the formulation, production and marketing of nutraceuticals, resulting from continuous research and development. The activity is organized around 3 poles:
- Diètnatural: a format designed and developed by the company, dedicated to the sale of nutraceutical products dedicated to slimming and continuous assistance through operators specialized in nutrition within the framework of wellness therapy;
- Medical Division: a line of nutraceutical products launched in 2021, dedicated to three specific therapeutic areas (gastroenterology, neurology and musculoskeletal) with major developments planned in the orthopedic field;
- BodySano: a French format integrated in 2023 following the acquisition of a majority interest in BodySano France (now Erfo France) and focused on offering new methods of nutritional coaching associated with the commercialization of dietary supplements and beauty treatments with innovative tools.
- Diètnatural: a format designed and developed by the company, dedicated to the sale of nutraceutical products dedicated to slimming and continuous assistance through operators specialized in nutrition within the framework of wellness therapy;
- Medical Division: a line of nutraceutical products launched in 2021, dedicated to three specific therapeutic areas (gastroenterology, neurology and musculoskeletal) with major developments planned in the orthopedic field;
- BodySano: a French format integrated in 2023 following the acquisition of a majority interest in BodySano France (now Erfo France) and focused on offering new methods of nutritional coaching associated with the commercialization of dietary supplements and beauty treatments with innovative tools.
Source: Cofisem - Last Update: 2024-05-08
Key Executives
| Chairman and Chief Executive Officer | |
| Chief Investor Relations Officer | |
| Chief Financial Officer |
Source: Cofisem - Last Update: 2024-05-08
Key Figures
| Millenium | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Net sales | 5,737,059 | 4,624,287 | 4,818,434 | 3,904,323 | 4,348,805 |
| Consumed purchases | 1,662,370 | 1,319,870 | 1,370,627 | 1,078,758 | 1,188,229 |
| Labour costs | 1,036,069 | 890,572 | 694,251 | 654,178 | 772,173 |
| Operating profit | 836,742 | 987,032 | 1,580,046 | 1,487,526 | 1,807,954 |
| Income tax | 224,830 | 232,433 | 389,859 | 350,878 | 483,776 |
| Net income | 590,330 | 716,072 | 1,165,976 | 1,139,930 | 1,310,094 |
| Net income (Group share) | 553,815 | 716,072 | 1,165,976 | 1,139,930 | 1,310,094 |
| Fiscal year end | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - unit | EUR - unit | EUR - unit | EUR - unit | EUR - unit |
| Account Standards | Local GAAP | Local GAAP | Local GAAP | Local GAAP | Local GAAP |
Source: Cofisem - Last Update: 2024-05-08
Shareholder information
| Active Capital Investment | |
| Group-owned stock | |
| Free float |
Source: Cofisem - Last Update: 2024-05-08
Address
Laboratorio Farmaceutico Erfo S.p.A.
Viale Geki Russo 9
IT-98049 Villafranca Tirrena
Italy
Phone number: +39 090 914 6125
https://www.erfo.it/investor-relations-and-governance/
Source: Cofisem - Last Update: 2024-05-08
Contact
Daniele Travisano
Phone number: 090 914 6125
IR@ERFO.IT
Phone number: 090 914 6125
IR@ERFO.IT
Source: Laboratorio Farmaceutico Erfo S.p.A. - Last Update: 2024-05-08
Please contact MyQuestion.Italy@euronext.com for Company Profile support.